Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences Ltd has informed BSE that its Board of Directors will meet on Wednesday, 14th May 2025 to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and financial year ending 31st March 2025. The filing is made under Regulation 29 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The trading window for designated persons and their immediate relatives has been closed since 1st April 2025 and will remain closed until 48 hours after the results are declared. The signed intimation is filed by Chintan Doshi, Company Secretary and Compliance Officer.
This is a routine regulatory intimation ahead of the FY25 audited results announcement on 14th May. Investors should watch the results declaration for actual financial performance and any management commentary shared during the meeting.